PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates

被引:61
作者
Kamata, Shotaro [1 ]
Oyama, Takuji [2 ]
Saito, Kenta [1 ]
Honda, Akihiro [1 ]
Yamamoto, Yume [1 ]
Suda, Keisuke [1 ]
Ishikawa, Ryo [1 ]
Itoh, Toshimasa [3 ]
Watanabe, Yasuo [4 ]
Shibata, Takahiro [5 ]
Uchida, Koji [6 ]
Suematsu, Makoto [7 ]
Ishii, Isao [1 ]
机构
[1] Showa Pharmaceut Univ, Lab Hlth Chem, Machida, Tokyo 1948543, Japan
[2] Univ Yamanashi, Fac Life & Environm Sci, Kofu, Yamanashi 4008510, Japan
[3] Showa Pharmaceut Univ, Lab Drug Design & Med Chem, Machida, Tokyo 1948543, Japan
[4] Showa Pharmaceut Univ, Lab Pharmacol, Machida, Tokyo 1948543, Japan
[5] Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan
[6] Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan
[7] Keio Univ, Dept Biochem, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan
基金
日本科学技术振兴机构;
关键词
PROLIFERATOR-ACTIVATED RECEPTORS; CRYSTALLIZATION; RECOGNITION; SELECTIVITY;
D O I
10.1016/j.isci.2020.101727
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Most triacylglycerol-lowering fibrates have been developed in the 1960s-1980s before their molecular target, peroxisome proliferator-activated receptor alpha (PPAR alpha), was identified. Twenty-one ligand-bound PPAR alpha structures have been deposited in the Protein Data Bank since 2001; however, binding modes of fibrates and physiological ligands remain unknown. Here we showthirty-four X-ray crystallographic structures of the PPAR alpha ligand-binding domain, which are composed of a "Center'' and four "Arm'' regions, in complexes with five endogenous fatty acids, sixfibrates in clinical use, and six synthetic PPAR alpha agonists. High-resolution structural analyses, in combination with coactivator recruitment and thermostability assays, demonstrate that stearic and palmitic acids are presumably physiological ligands; coordination to ArmIII is important for high PPAR alpha potency/selectivity of pemafibrate and GW7647; and agonistic activities of four fibrates are enhanced by the partial agonist GW9662. These results renew our understanding of PPAR alpha ligand recognition andcontribute to the molecular design of next-generation PPAR-targeted drugs.
引用
收藏
页数:28
相关论文
共 42 条
[11]   A structural mechanism for directing corepressorselective inverse agonism of PPARγ [J].
Brust, Richard ;
Shang, Jinsai ;
Fuhrmann, Jakob ;
Mosure, Sarah A. ;
Bass, Jared ;
Cano, Andrew ;
Heidari, Zahra ;
Chrisman, Ian M. ;
Nemetchek, Michelle D. ;
Blayo, Anne-Laure ;
Griffin, Patrick R. ;
Kamenecka, Theodore M. ;
Hughes, Travis S. ;
Kojetin, Douglas J. .
NATURE COMMUNICATIONS, 2018, 9
[12]   Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode [J].
Capelli, Davide ;
Cerchia, Carmen ;
Montanari, Roberta ;
Loiodice, Fulvio ;
Tortorella, Paolo ;
Laghezza, Antonio ;
Cervoni, Laura ;
Pochetti, Giorgio ;
Lavecchia, Antonio .
SCIENTIFIC REPORTS, 2016, 6
[13]   Discovering highly selective and diverse PPAR-delta agonists by ligand based machine learning and structural modeling [J].
Da'adoosh, Benny ;
Marcus, David ;
Rayan, Anwar ;
King, Fred ;
Che, Jianwei ;
Goldblum, Amiram .
SCIENTIFIC REPORTS, 2019, 9 (1)
[14]   Coot:: model-building tools for molecular graphics [J].
Emsley, P ;
Cowtan, K .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2004, 60 :2126-2132
[15]   How good are my data and what is the resolution? [J].
Evans, Philip R. ;
Murshudov, Garib N. .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2013, 69 :1204-1214
[16]   Combination statin-fibrate therapy: safety aspects [J].
Franssen, R. ;
Vergeer, M. ;
Stroes, E. S. G. ;
Kastelein, J. J. P. .
DIABETES OBESITY & METABOLISM, 2009, 11 (02) :89-94
[17]   Recombinant human PPAR-β/δ ligand-binding domain is locked in an activated conformation by endogenous fatty acids [J].
Fyffe, SA ;
Alphey, MS ;
Buetow, L ;
Smith, TK ;
Ferguson, MAJ ;
Sorensen, MD ;
Björkling, F ;
Hunter, WN .
JOURNAL OF MOLECULAR BIOLOGY, 2006, 356 (04) :1005-1013
[18]   Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs [J].
Graham, DJ ;
Staffa, JA ;
Shatin, D ;
Andrade, SE ;
Schech, SD ;
La Grenade, L ;
Gurwitz, JH ;
Chan, KA ;
Goodman, MJ ;
Platt, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21) :2585-2590
[19]  
Han L, 2017, FUTUR CARDIOL, V13, DOI 10.2217/fca-2016-0059
[20]   Crystallization of protein-ligand complexes [J].
Hassell, Anne M. ;
An, Gang ;
Bledsoe, Randy K. ;
Bynum, Jane M. ;
Carter, H. Luke, III ;
Deng, Su-Jun J. ;
Gampe, Robert T. ;
Grisard, Tamara E. ;
Madauss, Kevin P. ;
Nolte, Robert T. ;
Rocque, Warren J. ;
Wang, Liping ;
Weaver, Kurt L. ;
Williams, Shawn P. ;
Wisely, G. Bruce ;
Xu, Robert ;
Shewchuk, Lisa M. .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2007, 63 :72-79